A phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen

Clinical Cancer Research

Volumn 5, Issue 6, 1999, Pages 1331-1338

  Morse, Michael A ^a   Deng, Yuping ^a   Coleman, Doris ^a   Hull, Shelley ^a   Kitrell Fisher, Eva ^a   Nair, Smita ^a   Schlom, Jeffrey ^b   Ryback, Mary Ellen ^c   Lyerly, H Kim ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA ANTIGEN CLASS 2; INTERLEUKIN 4; PEPTIDE FRAGMENT;

ACTIVE IMMUNIZATION; ADULT; AGED; ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ARTICLE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DENDRITIC CELL; DRUG SAFETY; FEMALE; HLA SYSTEM; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; INTRAVENOUS DRUG ADMINISTRATION; MALE; METASTASIS; MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; T LYMPHOCYTE; TRANSDERMAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, ANTINUCLEAR; ANTIGENS, CD; CARCINOEMBRYONIC ANTIGEN; CELLS, CULTURED; DENDRITIC CELLS; FEMALE; HLA-A2 ANTIGEN; HUMANS; IMMUNOTHERAPY, ACTIVE; MALE; MIDDLE AGED; NEOPLASMS; PEPTIDE FRAGMENTS; RHEUMATOID FACTOR; SURVIVAL RATE; TRANSPLANTATION, AUTOLOGOUS;

EID: 0033017065     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Thompson, J. A., Grunert, F., and Zimmermann, W. Carcinoembryonic antigen gene family: molecular biology and clinical prospectives. J. Clin. Lab. Anal., 5: 344-366, 1991.
2. Van der Bruggen, P. C., Traversari, C., Chomez, P., Lurquin, C., De Plaen, E., Van den Eynde, B., Knuth, A., and Boon, T. A gene encoding an antigen recognized by cytotoxic T lymphocytes on a human melanoma. Science (Washington DC), 254: 1643-1647, 1991.
3. Disis, M. L., and Cheever, M. A. HER-2/neu protein: a target for antigen-specific immunotherapy of human cancer. Adv. Cancer Res., 71: 343-371, 1997.
4. Kawakami, Y., Eliyahu, S., Delgado, C. H., Robbins, P. F., Rivoltini, L., Topalian, S. L., Miki, T., and Rosenberg, S. A. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc. Natl. Acad. Sci. USA, 91: 3515-3519, 1994.
5. Barnd, D. L., Lan, M. S., Metzgar, R. S., and Finn, O. J. Specific MHC-unrestricted recognition of tumor associated mucins by human cytotoxic cells. Proc. Natl. Acad. Sci. USA, 86: 7159-7163, 1989.
6. Banchereau, J., and Steinman, R. M. Dendritic cells and the control of immunity. Nature (Lond.), 392: 245-252, 1998.
7. Celluzzi, C. M., Mayordomo, J. I., Storkus, W. J., Lotze, M. T., and Falo, L. D., Jr. Peptide-pulsed dendritic cells induce antigen-specific, CTL-mediated protective tumor immunity. J. Exp. Med., 183: 283-287, 1996.
8. Flamand, V., Sornasse, T., Thielernans, K., Demanet, C., Bakkas, M., Bazin, H., Tielemans, F., Leo, O., Urbain, J., and Moser, M. Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivo. Eur. J. Immunol., 24: 605-610, 1994.
9. Paglia, P., Chiodoni, C., Rodolfo, M., and Colombo, M. P. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J. Exp. Med., 183: 317-322, 1996.
10. Porgador, A., Snyder, D., and Gilboa, E. Induction of antitumor immunity using bone marrow-generated dendritic cells. J. Immunol., 156: 2918-2926, 1996.
11. Porgador, A., and Gilboa, E. Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes. J. Exp. Med., 182: 255-260, 1995.
12. Ossevoort, M. A., Feltkamp, M. C. W., Van Veen, K. J. H., Melief, C. J., and Kast, W. M. Dendritic cells as carriers for a cytotoxic T-lymphocyte epitope-based peptide vaccine in protection against: a human papillomavirus type 16-induced tumor. J. Immunother., 18: 86-94, 1995.
13. Mayordomo, J. I., Zorina, T., Storkus, W. J., Zitvogel, L., Celluzzi, C., Falo, L. D., Melief, C. J., Ildstad, S. T., Kast, W. M., Deleo, A. B., and Lotze, M. T. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat. Med., 12: 1297-1302, 1995.
14. Morse, M. A., Zhou, L-J., Tedder, T. F., Lyerly, H. K., and Smith, C. Generation of dendritic cells in vitro from peripheral blood mononuclear cells with GM-CSF, IL-4, and TNF-α for use in cancer immunotherapy. Ann. Surg., 226: 6-16, 1997.
15. Romani, N., Reider, D., Heuer, M., Ebner, S., Kampgen, E., Eibl, B., Niederwieser, D., and Schuler, G. Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability. J. Immunol. Methods, 196: 137-151, 1996.
16. Bender, A., Sapp, M., Schuler, G., Steinman, R. M., and Bhardwaj, N. Improved methods for the generation of dendritic cells from nonproliferating progenitors in human blood. J. Immunol. Methods. 196: 121-135, 1996.
17. Morse, M. A., and Lyerly, H. K. Immunotherapy of cancer using dendritic cells. Cytokines Cell. Mol. Ther., 4: 35-44, 1998.
18. Hsu, F. J., Benike, C., Fagnoni, F., Liles, T. M., Czerwinski, D., Taidi, B., Engleman, E. G., and Levy, R. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat. Med., 2: 52-58, 1996.
19. Murphy, G., Tjoa, B., Ragde, H., Kenny, G., and Boynton, A. Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen. Prostate, 29: 371-380, 1996.
20. Nestle, F. O., Alijagic, S., Gilliet, M., Sun, Y., Grabbe, S., Dummer, R., Burg, G., and Schadendorf, D. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med., 4: 328-332, 1998.
21. Kantor, J., Irvine, K., Abrams, S., Kaufman, H., DiPietro, J., and Schlom, J. Antitumor activity and immune responses induced by a recombinant carcinoembryonic antigen-vaccinia virus vaccine. J. Natl. Cancer Inst., 84: 1084-1091, 1992.
22. Kantor, J., Irvine, K., Abrams, S., Snoy, P., Olsen, R., Greiner, J., Kaufman, H., Eggensperger, D., and Schlom, J. Immunogenicity and safety of a recombinant vaccinia virus vaccine expressing the carcinoembryonic antigen gene in a nonhuman primate. Cancer Res., 52: 6917-6925, 1992.
23. Mcaneny, D., Ryan, C. A., Beazley, R. M., and Kaufman, H. I. Results of a phase I trial of a recombinant vaccinia virus that expresses carcinoembryonic antigen in patients with advanced colorectal cancer. Ann. Surg. Oncol., 3: 495-500, 1996.
24. Tsang, K. Y., Zaremba, S., Nieroda, C. A., Zhu, M. Z., Hamilton, J. M., and Schlom, J. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J. Natl. Cancer Inst., 87: 982-990, 1995.
25. Wong, C., Morse, M., and Nair, S. K. Induction of primary, human antigen-specific cytotoxic T lymphocytes in vitro using dendritic cells pulsed with peptides. J. Immunother., 21: 32-40, 1999.
26. Bernhard, H., Disis, M. L., Heimfeld, S. Mortarini, R., Anichini, A., Lombardi, L., Ravagnani, F., Parmiani, G., and Gianni, A. M. Generation of immunostimulatory dendritic cells from human CD34+ hematopoietic progenitor cells of the bone marrow and peripheral blood. Cancer Res., 55: 1099-1104, 1995.
27. Siena, S., Di Nicola, M., Bregni, M., Mortarini, R., Anichini, A., Lombardi, L., Ravagnani, F., Parmiani, G., and Gianni, A. M. Massive ex vivo generation of functional dendritic cells from mobilized CD34+ blood progenitors for anti-cancer therapy. Exp. Hematol., 23: 1463-1471, 1995.
28. Strunk, D., Rappersberger, K., Egger, C., et al. Generation of human dendritic cells/Langerhans cells from circulating CD34+ hematopoietic progenitor cells. Blood, 87: 1292-1302, 1996.
29. Andreesen, R., and Hennemann, B. Adoptive immunotherapy with autologous macrophages: current status and future perspectives. Pathobiology, 59: 259-263, 1991.
30. Bryhni, B., Aanderud, S., Sundsford, J., Rekvig, O. P., and Jorde, R. Thyroid antibodies in northern Norway: prevalence, persistence and relevance. J. Intern. Med., 239: 517-523, 1996.
31. Fyssas, I., Syrigos, K. N., Konstantoulakis, M. M., Tsibloulis, V., Manouras, A., Peveretos, P., and Golematis, B. C. Thyroid autoantibodies and thyroid function in patients with pancreatic adenocarcinoma. Acta Oncol., 36: 65-68, 1997.
32. Puccetti, P., Bianchi, R., Fioretti, M. C., Ayroldi, E., Uyttenhove, C., van Pel, A., Boon, T., and Grohmann, U. Use of a skin test assay to determine tumor-specific CD8+ T cell reactivity. Eur. J. Immunol., 24: 1446-1452, 1994.
33. Morse, M. A., Lyerly, H. K., Gilboa, E., Thomas, E. K., and Nair, S. K. Optimization of the sequence of antigen loading and CD40-ligand-induced maturation of dendritic cells. Cancer Res., 58: 2965-2968, 1998.